Acetazolamide - CAS 59-66-5
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
Acetazolamide
Catalog Number:
59-66-5
Synonyms:
N-[5-Aminosulfonyl)-1,3,4-thiadiazol-2-yl]acetamide; 5-Acetamido-1,3,4-thiadiazole-2-sulfonamide; Acetamox; Atenezol; Defiltran;
CAS Number:
59-66-5
Description:
Acetazolamideis a carbonic anhydrase inhibitor used to treat glaucoma.
Molecular Weight:
222.25
Molecular Formula:
C4H6N4O3S2
Quantity:
Milligrams-Grams
Quality Standard:
Enterprise Standard
COA:
Inquire
MSDS:
Inquire
Canonical SMILES:
CC(=O)NC1=NN=C(S1)S(=O)(=O)N
InChI:
1S/C4H6N4O3S2/c1-2(9)6-3-7-8-4(12-3)13(5,10)11/h1H3,(H2,5,10,11)(H,6,7,9)
InChIKey:
BZKPWHYZMXOIDC-UHFFFAOYSA-N
Targets:
Carbonic Anhydrase
Chemical Structure
CAS 59-66-5 Acetazolamide

Related Carbonic Anhydrase Products


CAS 59-66-5 Acetazolamide

Acetazolamide
(CAS: 59-66-5)

Acetazolamideis a carbonic anhydrase inhibitor used to treat glaucoma.

CAS 120-97-8 Dichlorphenamide

Dichlorphenamide
(CAS: 120-97-8)

Dichlorphenamide is a sulfonamide and a carbonic anhydrase inhibitor of the meta-Disulfamoylbenzene class.

CAS 554-57-4 Methazolamide

Methazolamide
(CAS: 554-57-4)

Methazolamide is a carbonic anhydrase inhibitor with Ki of 50 nM, 14 nM and 36 nM for hCA I, hCA II and bCA IV isoforms, respectively.

CAS 4991-65-5 Tioxolone

Tioxolone
(CAS: 4991-65-5)

Tioxolone is a metalloenzyme carbonic anhydrase I inhibitor with a Ki of 91 nM.

CAS 138890-62-7 Brinzolamide

Brinzolamide
(CAS: 138890-62-7)

Brinzolamide is a potent carbonic anhydrase II inhibitor with IC50 of 3.19 nM.

CAS 73-49-4 quinethazone

quinethazone
(CAS: 73-49-4)

Quinethazone is a thiazide-like diuretic. It is a carbonic anhydrase inhibitor and can be used for the treatment of hypertension.

Reference Reading


1.Possible association between acetazolamide administration during pregnancy and multiple congenital malformations.
Al-Saleem AI1, Al-Jobair AM2. Drug Des Devel Ther. 2016 Apr 15;10:1471-6. doi: 10.2147/DDDT.S99561. eCollection 2016.
Congenital malformations might occur because of environmental or genetic factors, and sometimes occur because of unknown causes. Acetazolamide is a carbonic anhydrase inhibitor that is used to treat idiopathic intracranial hypertension, glaucoma, and epilepsy. The use of acetazolamide has not been recommended for pregnant women because of reported teratogenic risks. Congenital malformations, such as ectrodactyly, syndactyly, cleft lip/palate, and retarded incisor teeth development, have been reported in experimental animals. However, tooth agenesis due to the use of acetazolamide has not been reported yet. Oligodontia is a severe type of tooth agenesis involving six or more congenitally missing teeth. The causes of oligodontia are attributed to environmental factors, such as irradiation, drugs, trauma, tumors, infection, genetic factors, or a combination. There is no credible evidence of undesirable effects of acetazolamide use in human pregnancy.
2.Effect of acetazolamide on cytokines in rats exposed to high altitude.
Wang C1, Wang R2, Xie H3, Sun Y1, Tao R1, Liu W4, Li W1, Lu H1, Jia Z1. Cytokine. 2016 Apr 19;83:110-117. doi: 10.1016/j.cyto.2016.04.003. [Epub ahead of print]
Acute mountain sickness (AMS) is a dangerous hypoxic illness that can affect humans who rapidly reach a high altitude above 2500m. In the study, we investigated the changes of cytokines induced by plateau, and the acetazolamide (ACZ) influenced the cytokines in rats exposed to high altitude. Wistar rats were divided into low altitude (Control), high altitude (HA), and high altitude+ACZ (22.33mg/kg, Bid) (HA+ACZ) group. The rats were acute exposed to high altitude at 4300m for 3days. The HA+ACZ group were given ACZ by intragastric administration. The placebo was equal volume saline. The results showed that hypoxia caused the heart, liver and lung damage, compared with the control group. Supplementation with ACZ significantly alleviated hypoxia-caused damage to the main organs. Compared with the HA group, the biochemical and blood gas indicators of the HA+ACZ group showed no difference, while some cytokines have significantly changed, such as activin A, intercellular adhesion molecule-1 (ICAM-1, CD54), interleukin-1α,2 (IL-1α,2), l-selectin, monocyte chemotactic factor (MCP-1), CC chemokines (MIP-3α) and tissue inhibitor of matrix metalloproteinase 1 (TIMP-1).
3.Formulation design of oral pediatric Acetazolamide suspension: dose uniformity and physico-chemical stability study.
Santoveña A1, Suárez-González J1, Martín-Rodríguez C1, Fariña JB1. Pharm Dev Technol. 2016 Apr 24:1-7. [Epub ahead of print]
CONTEXT: The formulation of an active pharmaceutical ingredient (API) as oral solution or suspension in pediatrics is a habitual practice, due to the non-existence of many commercialized medicines in pediatric doses. It is also the simplest way to prepare and administer them to this vulnerable population. The design of a formulation that assures the dose and the system stability depends on the physico-chemical properties of the API.